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Background: Intravenous tranexamic acid (TXA) within 3 hours of 
birth significantly reduces death due to bleeding in women with 
postpartum haemorrhage (PPH). Most PPH deaths occur in the first 
hours after giving birth and treatment delay decreases survival.  One 
barrier to rapid TXA treatment is the need for intravenous injection. 
Intramuscular injection and oral solution of TXA would be easier and 
faster to administer and would require less training. However, the 
pharmacokinetics (PK), pharmacodynamics and safety of TXA 
administered by different routes in pregnant women have not been 
established. The main aim of this study is to ascertain whether IM and 
oral solution of TXA will be absorbed at levels sufficient to inhibit 
fibrinolysis in pregnant women. 
Methods: WOMAN-PharmacoTXA is a prospective, randomised, open 
label trial to be conducted in Zambia and Pakistan.  Adult women 
undergoing caesarean section with at least one risk factor for PPH will 
be included.  Women will be randomised to receive one of the 
following about 1 hour prior to caesarean section: 1-gram TXA IV, 1-
gram TXA IM, 4-grams TXA oral solution or no TXA. Randomisation will 
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continue until 120 participants with at least six post randomisation PK 
samples are included. TXA concentration in maternal blood samples 
will be measured at baseline and at different time points during 24 
hours after receipt of intervention. Blood TXA concentration will be 
measured from the umbilical cord and neonate. 
The primary endpoint is maternal blood TXA concentrations over time. 
Secondary outcomes include umbilical cord and neonate TXA 
concentration D-dimer concentration, blood loss and clinical diagnosis 
of PPH, injection site reactions and maternal and neonate adverse 
events. 
Discussion: The WOMAN-PharmacoTXA trial will provide important 
data on pharmacokinetics, pharmacodynamics and safety of TXA after 
IV, intramuscular and oral administration in women giving birth by 
caesarean section. 
Trial registration: ClincalTrials.gov, NCT04274335 (18/02/2020).
Keywords 
Antifibrinolytic, clinical trial, Tranexamic acid, PPH, intramuscular, oral, 
Pharmacokinetics, Pharmacodynamics, caesarean section
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Background
Postpartum haemorrhage (PPH) is a leading cause of maternal 
mortality and morbidity. About 14 million women suffer 
a PPH every year after childbirth and about 100,000 die if 
bleeding is not controlled1. Most PPH deaths occur in low- and 
middle-income countries (LMICs)2–5. Of those who survive, 
many suffer severe morbidity and need major interventions to 
control bleeding, including exploratory laparotomy, brace sutures 
and hysterectomy.
Tranexamic acid (TXA) is an antifibrinolytic drug. It binds to 
the lysine receptors on plasminogen blocking the conversion 
from plasminogen to the proteolytic enzyme plasmin, thereby 
preventing fibrin degradation and stabilising blood clots6,7. 
Intravenous TXA reduces blood loss in surgery and increases 
survival in traumatic bleeding and PPH. The WOMAN trial 
showed that giving intravenous TXA reduced the risk of death 
from PPH8. TXA treatment, as early as possible and no later 
than 3 hours, reduced PPH deaths by one third and the need 
for laparotomy to control bleeding by over one third.
Most deaths from PPH occur within the first hours after giv-
ing birth. The survival benefit of TXA reduces by 10% with 
every 15 minutes of treatment delay, and after 3 hours there is no 
benefit9. The need for intravenous administration of TXA is one 
of the main barriers for rapid treatment. Currently, TXA for 
PPH can only be given where trained healthcare professionals 
are available to give the drug intravenously. However, in many 
LMIC countries, a large number of women give birth at 
home with no access to trained personnel. Additionally, many 
nurses and midwives who care for women with PPH are not 
trained to give intravenous drugs.
Alternatives routes to IV TXA would make administration easier 
and faster and would require less training. TXA is available for 
oral administration (tablet and solution) and has the potential 
to be given by intramuscular injection.
However, there has been little research into different routes 
of administration and the pharmacokinetic (PK) properties 
of TXA in pregnant women have not yet been established.
Studies in healthy volunteers show that therapeutic plasma TXA 
levels (plasma TXA >10 mg/L)10 are reached rapidly (within 
30 min) after IM injection11–13. PK modelling of the oral admin-
istration of 4 g of TXA resulted in a plasma concentration of 
10 mg/L within 15 min (data on file). If absorption was simi-
larly rapid in pregnant women, this would strongly suggest 
the IM and oral routes as potential alternatives to IV use.
Recently, the Trauma-INTACT trial (ClinicalTrials.gov: 
NCT03875937) assessed the PK of TXA administered intra-
muscularly in bleeding trauma patients14. The study found that 
the time to reach therapeutic concentrations of 10 mg/L after 
intramuscular injection of 1 g TXA was within 15 min. Addi-
tionally, it was well tolerated with only mild injection site reac-
tions and no serious adverse events reported. The PharmacoTXA 
trial (ClinicalTrials.gov: NCT03777488) has assessed the 
PK of TXA administered intramuscularly or orally in healthy 
volunteers. An ongoing RCT called TRACES (TRAnexamic 
Acid to Reduce Blood Loss in Hemorrhagic CESarean Deliv-
ery) aims to assess the PK and pharmacodynamics (PD) effects 
of two doses of TXA (0.5 and 1 g) injected intravenously in 
women with an ongoing PPH after delivery15.
Physiologic changes induced by pregnancy and childbirth16 
may alter the PK and PD properties of medicines, in particular 
due to the increase in renal elimination clearance and volume of 
distribution.
PPH can occur without warning in most women. However, 
some risk factors such as multiple pregnancy, macrosomia or 
previous PPH, are known to be associated with an increased 
risk of PPH17,18.
In this study we will assess the PK, PD, safety and efficacy 
of TXA administered by IV, IM or oral routes in women giv-
ing birth by caesarean section (CS) with at least one risk fac-
tor for PPH. Blood samples will be taken from the women 
immediately before the administration of TXA (1 hour before 
CS) and at different time points during 24 hours after receipt 
of intervention. Blood samples from the umbilical cord after 
clamping and from newborns (obtained from the sample taken 
for routine heel prick test) will be taken to measure the amount 
of TXA transferred from the mother to the neonate via the pla-
centa. The efficacy of the different routes of TXA administra-
tion in preventing blood loss, reducing fibrinolytic activity, 
and the safety of the interventions will be evaluated.
Rationale
Hypothesis
We hypothesise that IM and oral solution of TXA will be 
well absorbed in pregnant women. Based on PK modelling of 
data available in the literature, we predict that a 1 g IM injec-
tion or 4 g oral solution administration of TXA will provide 
therapeutic TXA levels ≥10 mg/L in plasma10 within about 
30 minutes. 
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Description of trial population
Recruitment will continue until 120 adult women who are under-
going CS with at least one risk factor for PPH and who com-
plete the trial are included. 30 women will receive 1 gram of 
TXA by IV injection, 30 women will receive 1 gram of TXA 
by IM injection, 30 women will receive 4 grams of TXA orally, 
and 30 women will receive no TXA about 1 hour prior to the 
CS. Additionally, women will receive routine interventions for 
active management of 3rd stage of labour and if they develop 
PPH, all standard interventions should be given. There are 
no restrictions on treatment of co-morbidities.
Description of investigational product and justification 
of the dosage, route of administration, administration 
schedule and treatment duration
In this study, women will be randomised to four groups:
    1. IV TXA GROUP: 30 women will receive 1 g of TXA 
by IV route. IV TXA treatment rapidly achieves the 
plasma levels of TXA needed to inhibit fibrinolysis and 
prevent excessive bleeding. Pharmacological research 
has shown that an IV dose of 1 g TXA maintains thera-
peutic plasma levels for around 3 hours, the period when 
the risk of bleeding is greatest12,19. However, the TXA 
PK and PD in pregnant women has not been described 
so far.
    2. IM TXA GROUP: 30 women will receive 1 g of TXA 
by IM route. Studies of IM TXA in healthy volunteers 
report good absorption and no adverse effects11,12. The dose 
will be given as two 5 mL (0.5 g each) injections into the 
thigh (rectus femoris or vastus lateralis) or buttocks (glu-
teal muscles) muscles, depending on a clinical assess-
ment of muscle mass12. The 1 g dose (10 mL) is divided 
to reduce the volume injected (5 mL is considered the 
upper limit)20. The injections will be given using the 
most appropriate needle size for IM administration from 
the sites stock (1” between 19 - 25 gauge and from 1 ½ 
inches up to 3” for large adults) using the Z-track method 
to seal the medication in the muscle20.
    3. TXA SOLUTION ORALLY: 30 women will receive 
4 g of TXA oral solution. The dose was selected because 
of the 50% oral bioavailability and because previous and 
preliminary PK data show that the absorption through the 
oral route is much slower than through the IV or IM routes, 
with much lower maximal concentration (Cmax)12,13,19,21. 
Therefore, higher doses are needed to reach therapeu-
tic levels, according to simulations. The oral route (tablets 
or solutions) is well characterised22–24, but oral TXA PK 
and PD in pregnant women have not been described so 
far.
    4. NO TXA CONTROL: 30 women will receive no 
TXA and will be the control group for PD, blood loss and 
safety data.
Safety of TXA and potential benefits and risks for study 
participants
TXA has been in clinical use for decades and has a good 
safety profile. TXA reduces the risk of death due to bleeding in 
women with PPH and in patients with traumatic bleeding, with-
out an increase in adverse events. The WOMAN trial recruited 
20,060 women with PPH and showed that TXA reduces the 
death due to bleeding (RR=0.81, 95% CI 0.65 to 1.00), espe-
cially when administered within three hours of giving birth 
(RR=0.69, 95% CI 0.52 to 0.91)8. The CRASH-2 trial ran-
domised 20,211 patients with trauma and showed that 
TXA reduces deaths due to bleeding when given soon after 
injury25,26. The combined evidence from 40,138 patients 
recruited in the WOMAN and CRASH-2 trials indicates that 
TXA significantly increases survival from bleeding (odds ratio 
[OR]=1·20, 95% CI 1·08–1·33; p=0·001), the effect increases 
to 70% when the treatment is immediate after injury/childbirth 
(OR=1·72, 95% CI 1·42–2·10; p<0·0001)9. In surgery, intrave-
nous TXA reduces blood loss (RR=0.66, 95% CI 0.65 to 0.67) 
and the need for transfusion (RR=0.62, 95% CI 0.58 to 0.68) 
by about a third27,28.
The most common potential side-effects reported by manufac-
turers to be associated with use of TXA according to frequency 
are diarrhoea, vomiting and nausea29,30.
Most of the TXA is excreted in the urine unchanged within 
12 hours of administration. To prevent accumulation in cases 
of renal impairment, women with known renal insufficiency 
are excluded from participating in this study. In addition, 
because a single dose of 1 g (IV or IM) or 4 g (oral) is used in 
the WOMAN-PharmacoTXA trial, there will be no risk of 
accumulation.
The absolute risk of thromboembolism amongst pregnant and 
postpartum women is estimated to be around 2 to 3 per 1,000 
woman-years. Even with a low risk, the incidence of throm-
boembolic events is four times higher amongst pregnant and 
post-partum women than in non-pregnant women of the 
same age31. There was no increase in the risk of venous throm-
bosis in the participants treated with TXA in the WOMAN trial. 
Given that severe bleeding may lead to vascular occlusive events 
it is possible that, by reducing bleeding, TXA also reduces 
the risk of thrombosis32.
TXA passes into breast milk in very low concentrations, 
approximately one hundredth of the concentration in maternal 
blood33–35. One study reported that growth and develop-
ment parameters were similar in children exposed to TXA 
through breastmilk compared to unexposed children, with no 
long-term adverse events33. No adverse events in breastfed 
babies were found in the WOMAN trial8.
TXA administered to pregnant women crosses the placenta 
and TXA concentration in the umbilical cord blood is similar 
to the concentration in the maternal blood36,37. The half-life of 
TXA in serum is 1–2 hours38, which would result in the elimi-
nation of TXA from the body within a few hours. Information 
is limited on the potential adverse effects on neonates 
of TXA administered to women before CS.
One study reported that no side effects were observed in new 
born babies from 12 healthy mothers who received TXA 
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10–20 min before CS delivery36. In three trials, 1 g of TXA 
was administered 10–20 minutes before CS, and no adverse 
events to mothers and neonates were reported in two of them34. 
One of the three studies reported that some mild and transient 
side effects occurred, but did not specify what kind of effects, 
how many participants were affected, and if any of these effects 
affected the babies39. A systematic review on the prophylactic 
use of TXA in cases of elective CS or abdominal myomec-
tomy included 16 trials with a total of 2,949 patients (2,789 
underwent CS)40. Only one of the eligible studies reported 
thromboembolic events that occurred in two patients in the 
TXA group, and two in the control group. This review did 
not report any side effects of prophylactic TXA on neonates. 
Similarly, a systematic review on the prophylactic use of TXA 
in women undergoing CS included 21 trials with a total of 
3,852 patients41. Also this review did not report any adverse 
events in the mothers, except for the four cases of thromboem-
bolic events reported in the same trial included in the previous 
review. A review on guidelines and relevant data on the use of 
TXA in PPH prophylaxis for CS and vaginal delivery reported 
that the only evidence of possible adverse events for the mother 
concerned poor renal outcome in a case series study with 18 
patients with renal cortical necrosis in PPH where a TXA 
maintenance dose was used. The case series study reported 
that patients that did not recover normal renal function had 
a TXA maintenance dose of 0.5–1 g/h for a longer time 
(7.1 ± 4.8 h) compared to patients who recovered partial renal 
function (2.9 ± 2.4 h)42,43. This review confirmed that there are 
no reports of adverse neonatal outcomes associated with the 
administration of TXA shortly before giving birth to prevent 
PPH42. A systematic review on the effectiveness and safety 
of the use of TXA to prevent PPH that included 25 stud-
ies with a total of 4,747 participants concluded that there was 
no increased risk of deep vein thrombosis and an increased 
risk of minor transient events, i.e. nausea, vomiting, headache 
or dizziness44. The included studies that evaluated the safety 
of TXA on neonates reported that no adverse events occurred, 
and the Apgar score that assesses the baby’s health imme-
diately after birth showed no difference between babies in 
TXA-treated and control groups44.
No mutagenic activity of TXA has been detected in vitro 
and in vivo test systems45. No foetal abnormalities were iden-
tified in early dysmorphology and reproductive studies in 
animals45–47.
As the TXA will be delivered at the end of the 3rd trimester of 
pregnancy when the foetal development is complete, the trial 
treatment will not have any impact on foetal development.
The foreseeable risks related to the IM route of administra-
tion may include pain, redness and bruising at the injection site 
and a rare risk of infection at the injection site.
The study also involves additional blood samples from all par-
ticipants. We will take the smallest possible volume of blood 
that will allow us to carry out the analysis. The total vol-
ume of blood taken from the participating women (maximum 
of 35 mL over 24 hours) should have no clinical impact on 
the participant. One blood sample (2 × 10 µl) will be taken 
from the neonate at the time of the routine heel prick test.
We will routinely assess all women for nausea, vomiting, diar-
rhoea, thrombotic events, seizures and injection site reac-
tions as secondary outcomes. Additionally, all neonates will be 
routinely assessed for birth complications and adverse events.
Objectives and outcome measures/endpoints
Primary objective
To assess the population PK of IV, IM and oral TXA solution 
in pregnant women.
Secondary objectives
•    To assess the effect of the three routes of TXA administra-
tion on D-dimer concentration in blood samples.
•    To assess the concentration of TXA that crosses the placenta 
into the neonate via the three routes of administration.
•    To assess clearance of any TXA in neonate.
•    To assess the safety of the three routes of TXA 
administration.
•    To assess the effect of the three routes of TXA 
administration on postpartum bleeding.
Primary endpoint
Blood TXA concentrations over time in pregnant women.
Secondary endpoints
•    Blood concentrations of D-dimer over time
•    TXA concentration in umbilical cord and neonate 
after birth
•    Local reactions at IM injection sites
•    Adverse events (maternal and neonate)
•    Neonate status Apgar score
•    Measured blood loss from start of CS to 2 hours after
•    Clinical diagnosis of PPH
Trial design
A prospective, randomised, open label study to be conducted 
in obstetric units in Pakistan and Zambia. Potential eligi-
ble participants will undergo CS. Consent will be obtained 
as per section “Methods for informing and obtaining consent”.
Trial setting
Participants will be recruited from obstetric units in Pakistan 
and Zambia. Recruitment, treatment and follow-up will be 
conducted at the recruiting obstetric units. Names of participating 
sites will be listed on the trial website.
Participant eligibility criteria
Inclusion criteria
•    Women admitted to hospital giving birth by CS
•    History of at least one risk factor for PPH
•    Adult (≥18 years old)
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Exclusion criteria
•    Women giving birth vaginally
•    Women with a known allergy to TXA or its excipients
•    Women with current antepartum haemorrhage
•    Women known to have received TXA within 48 hours 
prior to randomisation
•    Women with known renal impairment
•    Women with any known blood clotting disorder
Trial procedures
Summary of trial procedures
The trial overview flow-chart is shown in Figure 1 the sum-
mary of trial procedures is shown in Figure 2. The protocol 
has been prepared according to the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) 2013 
guidelines48 (Additional files 1 and 2, Extended data)49. The 
complete copy of the protocol can be found in Additional 
file 3 (see Extended data)49.
Screening of potential participants
Potential eligibility will be assessed by a clinician at the par-
ticipating obstetric clinic when the woman is admitted for a 
CS.
Methods for informing and obtaining consent
Information giving. Women who are admitted for a CS with 
one risk factor for PPH will be given oral and written informa-
tion and fully informed consent will be obtained by the clini-
cian. If she is unable to read or write, the information sheet 
will be read to her, and she will mark the consent form with 
a cross or thumbprint. In this case, an impartial witness must 
be present throughout the procedure and provide a signature 
confirming the mark.
The clinician will explain the trial to the woman verbally in a 
language that she understands and provide a written participant 
information sheet (Additional file 4, Extended data)49. In brief, 
it will be explained that she will receive the usual care given to 
women having a CS at the hospital. The clinician will explain 
that if she accepts to participate, because she is at risk of 
increased post-partum bleeding she will receive a drug called 
tranexamic acid into a vein, or a muscle, or to swallow it, or she 
may receive no trial drug. We need to study this because 
injecting TXA into a muscle or swallowing it are easier than 
injecting it into a vein.
This would mean that the treatment could help many more 
women giving birth who are at a high risk of bleeding. The cli-
nician will explain to the woman the expected risks of the 
treatment to herself and the baby. If the woman objects to 
inclusion, her views will be respected. The clinician will explain 
to the woman that she has the right to withdraw from the trial 
at any time, without the need to justify the reason and with-
out any consequences on the care provided to her and her 
baby. An overview of the consent procedure is provided in 
Additional file 5 (see Extended data)49.
Documenting consent process. In all cases, the clinician obtain-
ing consent should record in the participant’s medical notes the 
method used for obtaining a participant’s consent. The clini-
cian should retain the original signed and dated consent form, 
a copy should be given to the woman.
Baseline data collection
Baseline parameters will be used to build a PK model that 
describes the TXA concentration in the blood over time following 
TXA administration. 
The following baseline data will be recorded:
•    Demographic (age) and anthropometric data (height and 
weight [body mass index and body surface area using 
the Du Bois formula will be derived]). Information 
on these parameters can be collected at baseline
•    Medical and pregnancy history
•    PPH risk factor(s)
•    CS planned date and time
•    Reason for CS
•    Vital signs including blood pressure, temperature, heart 
rate, and respiratory rate
•    Full blood count
•    Blood test to assess renal function (urea, creatinine, 
estimated glomerular filtration rate)
•    Any foetal abnormalities
•    Any foetal distress
Randomisation
After collecting baseline data, enrolled participants will be ran-
domised into one of the four groups described in “Descrip-
tion of investigational product and justification of the dosage, 
route of administration, administration schedule and treatment 
duration”. The sequence for each dosing cohort will be cre-
ated using computer-generated random numbers, using blocking 
to ensure the required balance in the allocation of participants 
to treatment arms. The allocation ratio will be 1:1:1:1. 
An IT coding expert supported by a statistician who are not 
involved in the conduct of the trial will prepare the randomi-
sation codes. Eligibility will be confirmed and randomisation 
done via an online database. Once the code is generated, the 
trial intervention will be prepared and administered by a trained 
trial team member. Participants and all trial staff will be blind 
to treatment allocation until randomisation is completed.
TXA administration and timing of biological samples
The time of the TXA administration is T
0
. One blood sample 
will be taken for PK prior to drug administration.
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Figure 1. Trial overview.
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Figure 2. Summary of trial procedures.
Page 8 of 21
Wellcome Open Research 2021, 6:157 Last updated: 07 JUL 2021
Post TXA administration blood samples will be taken at dif-
ferent time points during 24 h as per the schedules in Figure 3. 
We understand that the care of the participant takes priority 
over the sampling schema and that sample times will inevita-
bly differ from those indicated. If it is not possible to obtain a 
sample at the scheduled time, the sample should be collected 
as soon as feasible with the exact time of collection recorded. 
Reasons for any delay will be recorded. Where there are less 
than six evaluable PK samples obtained after TXA administra-
tion from a participant, this participant will be replaced in the 
study.
Pharmacokinetics: Finger prick blood samples (2 × 10 µL per 
sample) for TXA quantitation will be taken as per Figure 3.
Pharmacodynamics: Blood samples (3 mL of venous blood in 
tubes containing 3.2% sodium citrate) for D-dimer quantitation 
will be taken as per Figure 3.
Collection and storage of biological samples
Only one blood sample for PK analysis will be collected at 
baseline for women who are randomised to receiving no TXA. 
Samples for D-dimer, full blood count (FBC) and renal function 
will be collected.
Maternal blood will be taken from a cannula to avoid 
multiple venepuncture as follows:
Two samples of 3mL each will be taken for FBC and two sam-
ples of 3mL each for renal function. Blood samples will be 
collected in purple top EDTA tubes for FBC and yellow top 
tubes with separation gel and clot activator for renal function.
Five samples for D-dimer of 3 mL for each sample of blood to 
be taken in collection blue top tubes containing 3.2% sodium 
citrate. Blood samples for D-dimer, FBC, and renal func-
tion will be collected from the hospitals and analysed by a local 
central laboratory. The laboratory will be asked to store the 
sample used for D-dimer analysis until the end of trial to 
allow for repeat tests if needed. In the event of failure of any 
of the PK samples, this will be used as a back-up and will be 
destroyed at the end of the trial.
Each maternal PK sample require about 20 µL of blood taken 
using a Mitra® cartridge from a finger prick (2 × 10 µL samples 
taken on the 2 cartridges of the same device to have one 
primary and one confirmation sample if needed). Sites will be 
provided with written procedures on how to obtain the blood 
sample using the Mitra® cartridge. Cartridges will be labelled 
with the date and time the sample was taken and with the 
participant Study Identification number.
The total volume of blood taken (less than 35 mL) should 
have no clinical impact on the participant.
Figure 3. Timing of biological samples.
Page 9 of 21
Wellcome Open Research 2021, 6:157 Last updated: 07 JUL 2021
To obtain the umbilical PK blood sample, once the umbilical 
cord is clamped, it is wiped with antiseptic and a syringe and 
needle is inserted into the vein in the umbilical cord to withdraw 
a small amount of blood. PK samples from the umbilical 
cord and neonates will also be taken using the Mitra® 
cartridge system as described above.
A blood sample from the neonate (2×10 µL) will be taken 
using the Mitra® cartridge at the time of the routine clinical 
heel prick test to avoid additional heel pricks.
PK samples will be placed into suitable sealed biological sam-
ple shipping bags and sent weekly to Dr Grassin-Delyle’s 
laboratory at UFR Simone Veil - Santé, University Versailles 
Saint Quentin (2 avenue de la source de la Bièvre, 78180 
Montigny le Bretonneux, France) for PK analysis. No par-
ticipant identifiable data will be transferred to the laboratory. 
Once all analyses for this trial have been completed, all blood 
samples will be destroyed.
Follow-up assessments
The following parameters will be assessed and recorded dur-
ing the follow-up time of 7 days or until discharge, whichever 
is earlier:
Maternal:
•    Blood lost: Blood lost from incision to 2 hours after the 
CS will be estimated. The amount of blood in sponges 
and drapes used in surgery and blood loss from suctioning 
(excluding amniotic fluid) will be estimated. At the end of 
surgery, a calibrated obstetric drape will be used for 2 hours. 
•    Reaction at site of IM injections: Each IM injection site 
will be inspected for local reactions at the same time as 
PK blood sampling and then daily thereafter (for 7 days or 
until prior discharge).
•    Vital signs: Participants will have their blood pressure, tem-
perature, heart rate and respiratory rate recorded at the time 
of each PK blood sampling and daily until discharge or day 7.
•    Treatments: Data on treatments likely to influence PK 
levels of TXA (blood product transfusion and IV fluids 
administration, TXA or other antifibrinolytics) will be col-
lected from the time of TXA administration up to the time 
of the last PK sample.
•    Adverse events: As described in section “Pharmacovigilance”, 
will be recorded up to 7 days.
•    Clinical diagnosis of PPH: Clinical diagnosis of PPH up 
to 24 hours after birth (total blood loss of >1000 mL, or any 
blood loss sufficient to cause haemodynamic instability or 
requires further treatment).
Neonate:
•    Apgar score recorded 1 and 5 minutes after birth. This is a 
standard clinical test given to all newborns. This test checks 
a baby’s heart rate, muscle tone, and other signs to see if 
extra medical care or emergency care is needed.
•    Adverse events: As described in section “Pharmacovigilance”, 
will be recorded up to 7 days.
End of trial for participants
The trial ends at discharge, death or at 7 days, whichever 
occurs first.
Distinction between standard care and research
The only departure from standard care is the TXA given about 
1 hour prior to CS and extra blood sampling. Additionally, 
we will regularly inspect the IM injection sites.
Blood sample analysis
TXA quantitation. TXA will be measured with liquid chro-
matography coupled to mass spectrometry according to an 
analytical method validated following the European Medical 
Agency (EMA) guideline on bioanalytical method validation 
(EMEA/CHMP/EWP/192217/2009Rev.1 Corr.2)50. The method 
is linear in the range 0.1–1000.0 µg/mL, accuracy is between 
85.9 and 110.8% and precision <8.2%.
D-dimer quantitation. Blood for D-dimer assays will be assayed 
at a central laboratory. A citrate-containing tube will be prop-
erly filled and mixed via inversion. It will be transported to 
the laboratory and analysed within 3 hours. Quantification 
will be done by immunoassay.
Premature exit of trial participant
Participants may exit the study at any time and for any rea-
son. A previously given consent can be withdrawn. The inves-
tigator can withdraw a participant from the trial for any safety 
reason or if it is in the participant’s best interest.
If a participant exits the trial prematurely or withdraws con-
sent or refuses consent for continuation, data collected up to 
time of premature exit will be used. Participants who with-
draw from the trial with less than six post treatment PK 
samples will be replaced to ensure the four intervention groups 
remain balanced.
Monitoring participants after the premature termination of 
treatment. In case of an adverse event to the participant or her 
baby, the investigator will complete an adverse event report 
and monitor the event until the end of her participation in 
the research or until it has resolved or reached a stable state.
Procedure for replacing participants. If consent procedures 
are complete but the TXA dose is not given in full, the 
participant will be replaced.
When oral TXA is given and the participant vomits within 
the first hour of receiving the intervention, this participant 
will be replaced in the study. However, data collection for the 
participant will continue to the trial end.
Where the CS is delayed and takes place more than 2 hours 
after the administration of the intervention, the participant 
will be replaced in the study. However, data collection for the 
participant will continue to the trial end.
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If a participant receives the TXA dose but there are less than 
six post treatment evaluable PK samples obtained after TXA 
administration, this participant will be replaced in the study. 
However, data collection for the participant will continue 
to the trial end.
Data collected from the replaced participants will be used.
Trial treatment
Description and regulatory status of investigational 
medicinal product(s)
TXA is sold globally under a variety of trade names for the 
treatment of bleeding due to general or local fibrinolysis in 
adults and children from one year of age30. Several brands 
are licenced for use globally.
Participants will receive a licenced marketed form of TXA 
which will be purchased in each country.
Known drug reactions and interaction with other 
therapies
TXA solution for injection should not be added to blood for 
transfusion, or to injections containing penicillin.
Trial restrictions and the use of concomitant medication
Participants should receive all clinically indicated treatments. 
There is no restriction on the use of concomitant medica-
tion. In the event non-trial TXA is given during the time of the 
PK blood sampling, the dose, route of administration, date and 
time should be recorded on the case report form (CRF).
Assessment of compliance with treatment
IV, IM or oral TXA will be given by investigators at the 
participating site who will record the date and time of admin-
istration and who administered the investigational medicinal 
product (IMP). For the IM route, the body location of each TXA 
injection will also be recorded. If the IMP is not fully admin-
istered, the reason for this will be recorded in the CRF. The 
following will not be considered non-compliance with the 
protocol: where a participant dies before receipt of the IMP 
or where a clinical or protocol allowed reason is given for 
non-administration of the IMP.
Pharmacovigilance
Maternal events which occur as a consequence of the CS, or 
events which commonly occur in this population independ-
ent of exposure to the TXA administration, and those which are 
study endpoints do not need to be reported as an adverse event. 
Congenital or genetic abnormalities in neonates do not need to 
be reported as adverse events as these events are collected rou-
tinely. All other events fulfilling the criteria below should be 
reported. If a participant (both maternal and neonate) develops 
an adverse event, they should be treated in line with local pro-
cedures. In the definition below, participant refers to both 
maternal and neonate (s).
The flow chart of the safety reporting is shown in Additional 
file 6 (see Extended data)49.
More details on pharmacovigilance are available in Additional 
file 3 (see Extended data)49.
The type and duration of the follow-up of participants 
after adverse reactions
Each IM injection site will be monitored as detailed in sec-
tion “Follow up assessments”. Adverse events in the partici-
pant and her baby (ies) will be monitored up to day 7 or until 
death or discharge whichever is earlier. Any suspected unex-
pected serious adverse reaction (SUSAR) will need to be 
reported to the Sponsor irrespective of how long after IMP 
administration the reaction has occurred. All adverse events 
will need to be followed up until it has resolved or has reached 
a stable state.
Statistics and data analysis
Sample size calculation
Using PFIM 3.2.1 software51 and based on the population phar-
macokinetic parameters determined in a meta-analysis of the 
different pharmacokinetic studies published in healthy volun-
teers and data through the IV route in trauma patients13,52, a 
sample size of 120 participants will allow estimates (relative 
standard errors < 30%) of the pharmacokinetic parameters 
of the intravenous, intramuscular and oral administration of 
TXA. Optimal maternal blood sampling times were evalu-
ated and are as follows: immediately before TXA administra-
tion, and 15, 30 minutes, 1h, 2h, 4h, 8h, 12h and 24h after TXA 
administration. However, if in exceptional circumstances a 
sample cannot be taken at the optimal stated time, flexibility 
in blood sampling is allowed as detailed in the section “TXA 
administration and timing of biological samples”. The actual 
sampling time must be recorded.
Planned recruitment rate
Pregnant women will be enrolled until 120 participants with fully 
evaluable data are included. Evaluable participants must receive 
the full dose, not vomit the oral dose within 1 hour of admin-
istration, and have at least six post randomisation PK blood 
samples.
Statistical analysis plan
All statistical calculations will be performed using STATA, 
unless otherwise specified. All data will be presented in the 
form of summaries sorted by treatment group (cohort) and par-
ticipant ID. Tabular summaries will be presented based on the 
following grouping: IM, IV, Oral solution and No TXA.
For continuous variables, summary statistics will include 
sample size, mean, standard deviation, median, minimum, and 
maximum values. Frequencies and percentages will be 
calculated for categorical variables.
Pharmacokinetic analysis
All participants who receive the full dose of TXA and did not 
vomit the oral dose within the first hour and have at least six 
PK samples obtained after TXA administration to determine 
maternal plasma concentrations of TXA will be included in 
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the PK data analysis. The actual blood sampling times will be 
recorded and used in calculations for PK parameter estimation. 
TXA time-courses will be analysed using the nonlinear 
mixed effect modelling software program Monolix 2020R1 
version53, as previously described52,54–56. Briefly, parameters will 
be estimated by computing the maximum likelihood estima-
tor of the parameters without any approximation of the model 
(no linearization) using the stochastic approximation expecta-
tion maximization (SAEM) algorithm combined to a Markov 
chain Monte Carlo (MCMC) procedure (to ensure full conver-
gence, the MCMC will be fixed to 20 and the iteration number to 
1000). Different error models will be investigated (i.e. multi-
plicative, proportional and/or additive error models) to describe 
residual variabilities (expressed as σ, square root of σ2), and 
the between-subject variabilities (expressed as ω, square root 
of the variance ω2) will be ascribed to an exponential model. 
The Bayesian information criterion (BIC) will be used to test 
different hypotheses regarding the model, i.e.:
      i. covariate effect(s) on pharmacokinetic parameter(s)
     ii. residual variability model (proportional versus propor-
tional plus additive model)
    iii. structure of the variance-covariance matrix for the ω 
parameters.
Main covariates of interest in the population will be age, body-
weight (BW) and renal function, IV fluid and blood trans-
fusion volume. Parameter estimates will be standardised 











 is the standard value 




 are the parameter and covari-
ate values of the ith individual. The PWR exponents may be 
estimated from the data. However, for bodyweight, allomet-
ric scaling theory dictates that these are typically 0.75 and 1 for 
clearance and volumes terms, respectively46. The goodness-of-fit 
of each model will be evaluated by visual inspection of the 
individual concentration-time courses, the observed-predicted 
(population and individual) concentration scatter plots and 
the prediction-corrected visual predictive checks.
Placenta transfer and neonate heel prick PK levels: Concen-
trations will be presented in tabular form with mean, median, 
standard deviation and range as appropriate. For each time 
point, comparisons across groups will be done using the analy-
sis of variance. We will adjust for time between drug admin-
istration and sampling. Where both an umbilical cord and 
neonate heel prick sample is available, these will be used to 
build a PK model with gestational age and birth weight as the 
main covariates.
Pharmacodynamic analysis
D-dimer: Descriptive statistics for D-dimer concentration in 
maternal blood will be presented in tabular form with mean, 
median, standard deviation and range (minimum and maxi-
mum) as appropriate. For each time point, comparisons across 
groups will be done using the analysis of variance. The PK data 
will be combined, and analyses may be conducted to determine a 
relationship between exposure and the effect on D-dimers.
Safety parameters
Full blood count and renal function parameters: Descrip-
tive statistics for baseline and follow-up will be presented for 
each laboratory parameter. Changes from baseline as well as 
shift tables for laboratory parameters will be presented. All labo-
ratory values will be classified as normal, below normal (low), 
or above normal (high) based on normal ranges supplied by the 
central laboratory. Frequencies of abnormal values will be pre-
sented in tabular form. For purposes of analyses, laboratory 
results based upon standardized units will be used.
Vital signs: Descriptive statistics for blood pressure, heart, and 
respiratory rate will be presented in tabular form with mean, 
median, standard deviation and range (minimum and maxi-
mum) as appropriate. Number (%) of women with abnormal 
values in each randomised group will be presented.
Expected adverse events (collected routinely as outcomes 
for all participant): For each event, the number (%) of women 
in each randomised group will be presented.
Other adverse events: Adverse events will be coded by pri-
mary system organ class and preferred term using the Medical 
Dictionary for Regulatory Activities (MedDRA). The number 
of events (n) and number (%) of participants with events will be 
presented. Events will be presented separately for maternal and 
neonates.
IM injection skin reaction: Number (%) of women with a 
reaction and severity of reaction will be presented.
Efficacy
Blood loss at 2 hours: Descriptive statistics for maternal blood 
loss at 2 hours post-partum and total blood loss will be pre-
sented in tabular form with mean, median, standard deviation and 
range (minimum and maximum) as appropriate. Comparisons 
across groups will be done using the analysis of variance.
Clinical diagnosis of PPH: Number (%) of women in each 
randomised group will be presented.
Interim analysis
There are no planned interim analyses.
Procedure(s) to account for missing data
If one or more blood samples are not collected, the reason 
for this will be recorded in the CRF.




Information required in the research protocol will be col-
lected first onto a paper CRF and transferred to an electronic 
case report form (eCRF). The CRF can be viewed at https://ctu.
lshtm.ac.uk/woman-ptxa/. Anonymization of the participants 
will be ensured by using the trial participant’s screening number 
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as their unique ID. This will be recorded on each document 
needed for the research.
Data confidentiality
The persons responsible for the quality control of the study 
will take all necessary precautions to ensure the confidenti-
ality of information relating to the IMP, the study, the study 
participants and in particular the identity of the participants and 
the results obtained.
These persons, as well as the site investigators themselves, 
are bound by professional secrecy.
During and after the clinical study, all data collected about the 
study participants and sent to LSHTM CTU by the investigators 
(or sent to other collaborators) will be anonymised.
Under no circumstances will the names and addresses of 
participants be shown.
The trial will comply with relevant Data Protection regula-
tions including the European Union General Data Protection 
Regulation.
The Sponsor will ensure that appropriate consent is in place 
to access any personal information about the participant 
which is necessary for the quality control of the study.
Additional information on data processing and storage of docu-
ments and data is available in Additional file 3 (see Extended 
data)49.
Monitoring, audit and inspection
General organisation
The Sponsor (LSHTM) will ensure the safety and respect of indi-
viduals who have agreed to participate in the trial. The Spon-
sor have in place quality assurance systems for monitoring 
the implementation of the study at the study sites. To contact 
the Sponsor, see Additional file 7 (Extended data)49.
Monitoring
The trial will be conducted in accordance with the current 
approved protocol, International Conference on Harmonisation- 
Good Clinical Practice (ICH-GCP), each participating country’s 
relevant regulations and the trial’s written procedures. A moni-
toring plan will be made based on the risks identified in the 
risk assessment. The LSHTM Clinical Trials Unit (CTU) or 
country delegate will monitor the trial to ensure the rights, 
safety, and wellbeing of the trial participants and to ensure the 
accuracy of the data. All site investigators will be trained in the 
trial procedures and have extensive guidance. LSHTM CTU 
will require investigators and their institutions to provide access 
to source data and documents and all trial related documents for 
monitoring, audits, ethics committees review and regulatory 
inspection. All trial-related and source documents including 
medical records, original consent forms and original CRFs 
must be kept safely. Investigators must plan in advance of the 
trial start where the trial-related documents will be stored and 
how they will be accessed. All documents must be made avail-
able when required for monitoring/audit/inspection during the 
course of the trial and for up to 10 years after the end of the 
overall trial.
Audits/inspections
The Sponsor will also be responsible for auditing all aspects 
of the trial. The site Principal Investigators (PIs) agree to 
accept the quality assurance audits carried out by the Spon-
sor as well as the inspections carried out by relevant RECs and 
regulatory authorities to ensure adherence to the protocol, GCP 
and relevant regulations.
Ethical and regulatory considerations
Consent
Please see the section “Methods for informing and obtain-
ing consent” for details on methods for informing and obtaining 
consent from the research participants.
Legal obligations
The Sponsor’s role. This trial is sponsored by the LSHTM 
and its responsibilities coordinated by the LSHTM CTU. The 
CTU may delegate responsibilities to third parties which will 
be outlined in relevant agreements. The responsibilities of the 
CTU will be overseen by the Trial Management Group. with 
day to day responsibilities with the Trial Manager.
Peer review. The trial was funded after an open competition with 
blinded peer review by Wellcome and Bill & Melinda Gates 
Foundation.
Financial and other competing interests for the Chief Investi-
gator, Principal Investigators at each site and committee mem-
bers for the overall trial management. The personnel involved 
in this trial has no financial or other competing interests to dis-
close. PIs will be compensated for their time needed to oversee 
the trial conduct. Research staff will be employed at each 
site to carry out the trial procedures. An agreement with each 
site will be in place prior to the start of the trial.
Insurance
LSHTM accepts responsibility attached to its sponsorship 
of the trial and, as such, would be responsible for claims for 
any non-negligent harm suffered by anyone as a result of par-
ticipating in this trial. The indemnity is renewed on an annual 
basis and LSHTM assures that it will continue renewal of the 
indemnity for the duration of this trial.
Access to the final trial dataset
Each site will have continuous access to their own data as the 
trial is ongoing. The final dataset will be reviewed and pub-
lished by group authorship consisting of members of the Protocol 
Committee and key participating site collaborators.
Once all pre-planned analyses are completed, the totally ano-
nymised dataset, protocol, published manuscript, data dic-
tionary and any other relevant trial documents will be made 
freely available on the LSHTM CTU data platform.
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Dissemination policy
Dissemination policy
As Sponsor, LSHTM has the right and responsibility to ensure 
the results of this study are published. The main publica-
tion will be done as a group authorship consisting of the Proto-
col Committee. Once the pre-specified analysis is completed 
and data made freely available, anyone can use the trial data.
A final study report will be to be sent to the relevant regula-
tory authorities and ethics committees within one year of the 
end of the trial.
There are no plans to notify all participants of the outcome 
of the trial. However, participants can request a copy of 
the final results and each site will maintain a log of partici-
pants/families who would like a copy. LSHTM CTU provide 
copies to each site to send onwards.
Authorship eligibility guidelines and any intended use 
of professional writers
This study is being conducted as an academic collaboration. 
All parties who contribute significantly to this study will be 
named in the final publication.
Professional medical writers will not be hired to write 
dissemination material about the results of this trial.
Roles and responsibilities
Role of trial Sponsor and funder
The funders had no role in the design of the trial and will not 
have a role in its conduct, data collection, analysis, and inter-
pretation, manuscript preparation, review, and approval, and 
publication of the results. The Sponsor is responsible for the 
approval of any substantial amendment which may be needed 
to the protocol. After approval is given, the Sponsor must 
obtain, prior to implementing the amendment, approval from 
the relevant regulatory authorities and ethics committees. 
The Sponsor is responsible for reporting serious adverse events 
as per each country’s requirement and all serious breaches 
to relevant regulatory authority and ethics committees.
Roles and responsibilities of trial management groups 
and individuals
Protocol Development Committee: This includes the Chief 
Investigators (CIs), site PIs and participating clinicians and 
study staff. Its role is to ensure that the study protocol is sci-
entifically appropriate and that all ethical, regulatory and 
scientific aspects of the trial have been considered. If the pro-
tocol requires amending, this committee will review and rec-
ommend any changes. The final decision for any amendment 
to the protocol resides with the Sponsor.
Members of the Protocol Development Committee:
•     Haleema Shakur-Still: Study design, drafting and finalising 
the protocol
•     Ian Roberts: Study design, drafting and finalising the protocol
•     Rizwana Chaudhri: Study design
•     Stanislas Grassin-Delyle: Pharmacokinetic methods and 
analysis
•     Monica Arribas: Study design and drafting the protocol
Data Monitoring Committee (DMC): The primary respon-
sibility for monitoring and final decisions about safety of par-
ticipants in the trial lies with the Sponsor. Independent oversight 
of the safety of participants will be provided by an independent 
DMC. The composition of the DMC is provided in Additional 
file 8 (see Extended data)49.
The DMC will review on a regular basis accumulating safety 
data (adverse events and injection site reactions) from the ongo-
ing trial, and advise CIs regarding the continuing safety of cur-
rent participants and those yet to be recruited. Data on the 
type, frequency and severity of adverse events in mother and 
neonate will be reported to the DMC.
The DMC membership includes expertise in clinical trials, 
the use of TXA in obstetrics and gynaecology, care of women 
during childbirth and postnatal period and care of the newborn. 
The committee members are familiar with the safety profile of 
the drug.
The DMC Charter includes, but is not limited to, defining:
•    the schedule and format of the DMC meetings;
•    the format for presentation of data;
•    the method and timing of providing interim reports.
The DMC members are independent of the Sponsor, ethics 
committees, regulatory agencies, investigators, clinical care 
of the trial participants, and all trial operations.
Trial Management Group: The Trial Management Group 
will comprise the CI, trial manager, data manager and statisti-
cal expert. They will have responsibility for the day to day man-
agement of the trial. They will meet regularly to ensure that 
the trial is progressing according to the protocol.
PI’s responsibilities
Coordination within each participating hospital will be 
through a site PI whose responsibility will be detailed in an 
agreement in advance of starting the trial and will include:
•    personally supervise the study at site;
•    before and if needed during the trial, obtain all institutional 
appropriate approvals / favourable opinion;
•    delegate trial related responsibilities only to suitably 
trained and qualified personnel;
•    document delegation of duties to appropriately qualified 
persons;
•    train relevant medical, nursing and other staff to ensure 
that they remain aware of the state of the current 
knowledge, the trial and its procedures;
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•    agree to comply with the final trial Protocol and any 
relevant amendments;
•    ensure that all potentially eligible participants are 
considered promptly for the trial;
•    ensure consent is obtained in line with approved 
procedures;
•    ensure that the data are collected, completed and 
transmitted to the CTU in a timely manner;
•    ensure all adverse events are reported promptly to the 
CTU;
•    ensure blood samples are collected and prepared in line 
with the protocol and trial guidance;
•    ensure the investigator site file is up-to-date and 
complete;
•    account for trial drug at their site;
•    ensure appropriate storage of trial drug;
•    ensure the trial is conducted in accordance with 
ICH-GCP and relevant country-specific regulations 
including clinical trial regulations and data protection 
laws;
•    allow access to source data, including participants’ 
medical records for monitoring, audit and inspection;
•    be responsible for archiving all original trial documents 
including medical records, investigator’s study file, con-
sent forms and data forms for at 10 years after the end of 
the trial.
Ethics approval and consent to participate
The protocol was approved by the London School of Hygiene 
and Tropical Medicine’s Ethics Committee (ref: 21255), 
University of Zambia Biomedical Research Ethics Committee 
(UNZABREC, Ref: 933–2020), Zambia Medicines Regulatory 
Authority (ZAMRA, Reference: DMS/7/9/22/CT/102), Zambia 
National Health Research Authority (NHREB), National 
Bioethics Committee Pakistan (NBC, Ref:4-87/NBC-532/20/409), 
the Drug Regulatory Authority of Pakistan [DRAP, 
Reference: F. No. 16-16/2020 DD (PS)], the Ethical Review 
Board of MCH Centre-Pakistan Institute of Medical 
Sciences Hospital (Reference: F1-1/2015/ERB/SZABMU/583) 
and the Ethics Committee of the Federal Government Polyclinic 
Hospital (Reference: FGPC.1/12/2020/Ethical Committee) 
(Additional files 9, 10, 11, 12, 13, 14, 15, 16 in Extended data)49.
Discussion
The WOMAN-PharmacoTXA trial will provide important data 
on the PK, PD and safety of TXA and the comparison of IV, 
IM and oral administration in women giving birth by CS. The 
WOMAN trial, which studied the effect of TXA for the treat-
ment of PPH, showed that every 15 minutes delay in giving TXA 
reduced the benefit by 10%. If TXA given by IM or oral liquid 
route achieves therapeutic levels in blood to reduce bleeding, 
more women are likely to receive the treatment sooner. This trial 
is the first step toward developing another route of TXA admin-
istration to prevent PPH in settings where personnel trained to 
insert intravenous lines are not available.
Trial status
The current protocol is version 1.2, dated 3 April 2020 (see 
original protocol in Additional file 3. Extended data)49. The 
protocol was approved by the London School of Hygiene and 
Tropical Medicine’s Ethics Committee (ref: 21255), University 
of Zambia Biomedical Research Ethics Committee (UNZABEC, 
Ref: 933-2020), Zambia Medicines Regulatory Authority 
(ZAMRA, Reference: DMS/7/9/22/CT/102), Zambia National 
Health Research Authority (NHREB), the National Bioethics 
Committee Pakistan (NBC, Ref:4-87/NBC-532/20/409), the 
Drug Regulatory Authority of Pakistan [DRAP, Reference: F. 
No. 16-16/2020 DD (PS)], the Ethical Review Board of MCH 
Centre-Pakistan Institute of Medical Sciences Hospital (Refer-
ence: F1-1/2015/ERB/SZABMU/583) and the Ethics Commit-
tee of the Federal Government Polyclinic Hospital (Reference: 
FGPC.1/12/2020/Ethical Committee) (Additional files 9, 10, 
11, 12, 13, 14, 15, 16 in Extended data)49. Participant recruit-
ment began on the 18th December 2020. End of recruitment is 
planned for 30 June 2021 or when 120 fully evaluable participants 
have been recruited. 
Data availability
Underlying data
No underlying data are associated with this article.
Extended data
LSHTM Data Compass: WOMAN-PharmacoTXA Trial: Phar-
macokinetics and pharmacodynamics of tranexamic acid in 
women having caesarean section birth - Extended data. https://doi.
org/10.17037/DATA.0000216449.
This project contains the following extended data:
-    File02-WHO_trial_registration_dataset.docx (Additional 
file 02 - WHO WOMAN-PharmacoTXA trial registration 
dataset)
-    File03-WOMAN_PharmacoTXA_protocol.pdf (Additional 
file 03 - WOMAN PharmacoTXA tirial protocol)
-    File04-PIS_and_consent_form.pdf (Additional file 04 - 
Patient Information Sheet and Consent form)
-    File05-Consent_procedure_overview.pdf (Additional 
file 05 - Trial overview of the Consent procedure)
-    File06-Safety_reporting_flowchart.pdf (Additional file 
06 - Trial safety reporting flowchart)
-    File07-Main_contacts.pdf (Additional file 07 - Contact 
details of the Clinical Trials Unit- LSHTM and Sponsor)
-    File08-Data Monitoring Committee.pdf (Additional file 
08 - Composition of the Data Monitoring Committee)
-    File09-LSHTM_Ethics_approval.pdf (Additional file 
09 - LSHTM (Sponsor) Ethics Approval Letter)
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In this article, the authors describe the study protocol of a prospective randomized trial that will 
aim to assess the pharmacokinetics and pharmacodynamics of TXA administered either orally, 
intravenously, or intramuscular in woman undergoing elective C section.  
 
The primary objective and endpoint of the study will be to compare the pharmacokinetics profile 
of the 3 different routes of administration.  
 
The authors will also looked at fibrinolytic inhibition (using D-dimers), neonatal blood levels, and 
adverse events.  
 
The authors are presenting a strong clinical study that will certainly leads to clinical important 
finding. Finding alternative routes of administration of TXA in bleeding patients has been a priority 
to help reduce mortality associated with bleeding in low-income country. The present study will 
certainly be an important contribution to the literature.  
 
Two limitations can be identified in this protocol:  
 
1. Although d-dimers have been extensively used to estimate fibrinolytic activation, d-dimers are 
not specific and can be influenced by several other factors. It would have been interesting for the 
authors to include other traditional tests to estimate the degree of fibrinolytic activation/inhibition 
(e.g., t-PA activated ROTEM, plasmin generation, PAP complexes).  
 
2. The study is not designed or powered to compare the efficacy and safety of the different routes. 
However, this study is a crucial initial step to gather data and defined dose regimen before a large 
randomized controlled trial can be performed.
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Arribas et al. present a compelling need for determining alternative routes of TXA administration, 
particularly in low resource settings. An important contribution from their work will be adding 
information about transplacental TXA transfer and neonatal levels when TXA is giving prior to cord 
clamp. There are a few additional suggestions or items of clarification that can strengthen the 
manuscript: 
 
1) How was the TXA intravenous route administered - IV infusion or bolus? And were the start 
and/or end times of administration recorded? 
 
2) Please note on page 4 in the description of the IV TXA group there are a few more recently 
published studies of TXA PKPD in pregnant women (see citations below, some of which I was 
involved with1,2,3). The first citation listed also included some breast milk concentrations of TXA1. 
 
3) Were there pre-defined PD targets selected for d-dimer and if so what literature supported 
those?  
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4) In the three trials mentioned on top of page 5 where TXA was administered prior to cesarean, 
what was the 'n' of the participants studied? 
 
5) On page 5 a more recent TRAAP2 study (citation below4) findings are not included for 
preventative use of the TXA at the time of cesarean. 
 
6) When was cesarean section time defined? Time of entry into the operating theater or time of 
skin incision or time of delivery of baby? This would be good to clarify since interpretation of 
findings and time at sustained PK target given administration prior to delivery would be most 
relevant with respect to time of skin incision. At least in the US, surgical centers time of entry to 
room and time of skin incision can be variable (approx. 15 min to 45 min) depending on how long 
it takes to obtain regional anesthesia. 
 
7) To clarify further on estimated blood loss this was this clinically estimated by a primary surgeon, 
research staff member or any provider at the time of delivery? 
 
8) Given two central labs measured, d-dimer and this measurement can vary by machine/site - was 
this factored into consideration in the analysis plan? 
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